1. **Intended use**
To be used in the thin-layer chromatographic test for related substances according to the monograph for Chlortalidone in *The International Pharmacopoeia*.

2. **Caution**
For laboratory use only. Handle in accordance with good occupational hygiene, safety and laboratory practices and take precautions to avoid exposure. This material is not for administration to humans or animals. The corresponding safety data sheet can be accessed via the EDQM website (Reference Standards Database) or is available upon request from the EDQM (Helpdesk-FAQ section).

3. **Analytical data**

   **Infrared absorption spectrophotometry (IR):** A spectrum, 1.2 mg of 2-(4-chloro-3-sulfamoyl-benzoyl)benzoic acid in 300 mg of potassium bromide, is given in figure W181106.

   ![Infrared Spectrum](image_url)

   **High performance liquid chromatography (HPLC):** The purity was estimated by peak area normalization to 99.6% at 275 nm.

   **Thin-layer chromatography (TLC):** Two secondary spots were detected at 254 nm, when 100 µg were applied. The determination was performed according to the monograph for Chlortalidone.

   Rf (chlortalidone): 0.6

   Rf (2-(4-chloro-3-sulfamoylbenzoyl)benzoic acid): 0.3

   **Thermogravimetric analysis (TG):** When heated to 105°C a loss of 0.1% (w/w) was observed.

4. **Storage**
2-(4-Chloro-3-sulfamoylbenzoyl)benzoic acid should be kept in a tightly closed container, protected from light.
5. **Reference**
This certificate is extracted from the report, which is the basis for the adoption of this International Chemical Reference Substance by the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Twenty-ninth Report, WHO Technical Report Series, 704.

6. **Citation**
The user has an obligation to ensure that any reference made to the present Standard in any publication, presentation or public document (ex. scientific articles, data sheets for kits) bears the correct name, and code of the Standard and the correct name and address of EDQM as given in the present leaflet.

7. **Product liability**
The present Standard has been established by Apoteket SA, Sweden on behalf of the WHO. The Council of Europe, EDQM is responsible for storage and distribution.

   The Council of Europe makes no representation, contractual statement, or expression of opinion concerning the quality or safety of any item supplied, the presence of any defect in it, or its fitness for any particular purpose. The product must be handled by professional persons having technical skill and at their own discretion and risk. It is for the purchasers of any such item who are responsible for persons in a workplace to determine independently the risks associated with the item according to the conditions of use and to take appropriate safety measures, including provision of appropriate information to persons working with the substance. Any liability of the Council of Europe for injury, loss or damage arising from the supply or use of any such item is in any event hereby excluded to the fullest extent permitted by law; in particular, no liability is accepted for loss of profits or indirect or consequential loss.

8. **Disputes**
In accordance with the provisions of article 21 of the General Agreement on the Privileges and Immunities of the Council of Europe, all disputes between the Council of Europe (EDQM) and the customer as regards the application of this contract shall be submitted, if a mutual agreement cannot be reached between the parties, to arbitration as laid down in Order No. 481 of the Secretary General, approved by the Committee of Ministers.

9. **Signature**
This document is electronically signed by:

   **Dr Pierre Leveau**
   Head of the Quality, Safety and Environment Division